Autres langues Precipio, Inc.

Actions

PRPO

US74019L6020

Equipement et technologie médicale avancés

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 09/07/2026			Varia. 5j.	Varia. 1 janv.
26,48 ^USD	+1,38 %		+4,83 %	+15,23 %

19/05	Transcript : Precipio, Inc., Q1 2026 Earnings Call, May 18, 2026
14/05	Precipio, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Autres langues

29/06	Precipio, Inc.(NasdaqCM:PRPO) added to Russell 3000E Index
29/06	Precipio, Inc.(NasdaqCM:PRPO) added to Russell Microcap Index
29/06	Precipio, Inc.(NasdaqCM:PRPO) added to Russell 3000E Growth Benchmark
29/06	Precipio, Inc.(NasdaqCM:PRPO) added to Russell Microcap Growth Benchmark Index
12/06	Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
11/06	Precipio to Present at the Planet MicroCap Las Vegas
14/05	Precipio Announces Q1 2026 Financial Results
14/05	Precipio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Management team’s 2025 market-based Options have vested
06/05	Precipio Announces Q1-2026 Shareholder Update Call
30/03	Precipio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
30/03	Precipio, Inc. Auditor Raises 'Going Concern' Doubt
26/03	Plus Therapeutics, Inc Announces Board and Committee Changes, Effective on March 20, 2026
12/03	Precipio Announces Q4 and year-end 2025 Shareholder Update Call
10/03	Precipio Inc Announces Bloodhound BCR::ABL1 Assay For Chronic Myeloid Leukemia
10/03	Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
25/02	Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
15/01	Precipio Takes Major Steps Toward a Clean Balance Sheet
05/12	Precipio, Inc. to Showcase Its BCR::ABL1 Panel At 2025 Ash (American Society of Hematology) Meeting
05/12	Precipio to Showcase its BCR::ABL1 panel at 2025 ASH (American Society of Hematology) Meeting
04/12	Precipio identifies unauthorized access to isolated storage; no operational impact
04/12	Precipio Identifies Unauthorized Access to Isolated Storage; No Operational Impact
14/11	Specialty cancer diagnostics firm Precipio Q3 revenue rises 30% driven by new customers
14/11	Precipio Announces its Q3-2025 Financial Results
14/11	Precipio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025